On March 6 Xeris announced the refinancing of its existing senior secured term loan agreement with Hayfin Capital Management to provide the Company with a facility size of $200M at close, lowering its overall cost of capital and providing additional working capital to invest in the Company’s business plan. An additional $15.2 M will be available to settle, if needed, the outstanding senior convertible notes that mature mid-2025. In conjunction with the new loan agreement, Xeris paid the balance of the $15M debt facility to Hayfin, plus associated interest and fees.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on XERS:
- Options Volatility and Implied Earnings Moves Today, March 06, 2024
- XERS Upcoming Earnings Report: What to Expect?
- Biotech Alert: Searches spiking for these stocks today
- Xeris license pact with $75M potential for Xeriject formulation of teprotumumab
Questions or Comments about the article? Write to editor@tipranks.com